RARE Daily

C-Path and Centogene Sign MOU Collaboration in Lysosomal Disease Research and Drug Development

June 21, 2024

Rare Daily Staff

Critical Path Institute and Centogene signed a Memorandum of Understanding to advance drug development for lysosomal diseases and improve the quality of life for those impacted by these conditions.

The MOU outlines a strategic partnership aimed at leveraging both organizations’ strengths in genetic and real-world data to overcome barriers in developing safe and effective therapies for lysosomal diseases.

“This partnership with Centogene will enable us to combine our expertise and resources to overcome significant barriers in lysosomal disease research and drug development,” said Krista Casazza, scientific director of Critical Path for Lysosomal Diseases.

Centogene, a leader in genomic and multiomic testing services, utilizes advanced sequencing technologies to accelerate the diagnosis and development of treatments for rare and neurodegenerative diseases. The Centogene Biodatabank is the world’s largest real-world integrated multiomic data repository in rare and neurodegenerative diseases with more than 850,000 patients represented from more than 120 highly diverse countries, over 70 percent of whom are of non-European descent.

C-Path forms collaborative work groups comprised of diverse stakeholders to identify specific barriers to developing safe and effective therapies for a given disease. These focus groups then create tools and solutions that help drug developers overcome those barriers. Established in 2023, under the executive leadership of Amanda Klein, C-Path’s Critical Path for Lysosomal Diseases (CPLD) Consortium is a dynamic public-private partnership aimed at accelerating drug development for lysosomal diseases.

The MOU defines the collaborative potential between C-Path and Centogen, including data enrichment and linkage, genetic testing services, sample analysis reporting, access to Centogene’s biodatabank, and joint co-branding efforts.

“In partnering with C-Path, we are advancing our shared vision of transforming real-world data into life-saving therapeutics for patients around the world,” said Peter Bauer, chief medical and genomic officer at Centogene.

 

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube